Tackling the Serious Global Challenges in Infectious Disease

Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases

Advancing infectious disease drug development programs to provide solutions to patients, doctors, and society.

Leadership team skilled in advancing programs with upside potential

Active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization

Appili Therapeutics: Innovation Across a Broad Spectrum of Anti-Infectives

LATEST NEWS & EVENTS

Appili Therapeutics to Commence Trading on Main Board of the TSX Exchange
09/14/2020
Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA
09/11/2020
Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC
09/10/2020